Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors
On August 28, 2026, Stevanato Group SpA (STVN) shares fell 5.7%, closing at $21.03. The stock has experienced a volatile year, with a 52-week range of $12.89 to
STVN - Stevanato Group S.p.A.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$32.00
DETAILS
HIGH:
$32.00
LOW:
$32.00
MEDIAN:
$32.00
CONSENSUS:
$32.00
UPSIDE:
52.16%
Stock News
Stevanato Group Q2 Earnings Call Highlights
Stevanato Group (NYSE: STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary. Revenue for the quarter reached €302 million, up 8% both on a reported and constant-currency
Stevanato Group Q2 Earnings Call Highlights
Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group's proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark.
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discu.
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now
The shares of both stocks are down so far this year. Stevanato is benefiting from the need for GLP-1 injectables.
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
PIOMBINO DESE, Italy--(BUSINESS WIRE)-- #DiabetesTherapies--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism.
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders' Meeting”) held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, t.
Implied Volatility Surging for Stevanato Stock Options
Investors need to pay close attention to STVN stock based on the movements in the options market lately.
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.11 per share a year ago.
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions.
Stevanato Group to Participate in Three Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences: Tuesday, May 12, at 8:00 a.m. (PT) - Bank of America Global Healthcare Conference in Las Vegas, NV Tuesday, June 2, at 2:40 - 3:10 p.m. (CT) – William Blair Growth Stock Conference in Chi.
Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Price Targets
Stevanato Group S.p.A. (STVN) PT Lowered to $32 at KeyBanc
$32.00
(was $16.01)
Paul Knight
·
KeyBanc
Stevanato Group price target lowered to $17.50 from $23 at Jefferies
$17.50
(was $15.95)
Jefferies
Stevanato Group assumed with an Equal Weight at Morgan Stanley
$24.00
(was $22.58)
Morgan Stanley
Stevanato Group price target lowered to $28 from $30 at Citi
$28.00
(was $19.87)
Patrick Donnelly
·
Citigroup
Stevanato Group price target lowered to $22 from $26 at Morgan Stanley
$22.00
(was $21.71)
Drew Ranieri
·
Morgan Stanley
When Will Stevanato's Free Cash Flow Turn Positive? This Analyst Has An Answer
$33.00
(was $27.07)
Jacob Johnson
·
Stephens
Morgan Stanley Maintains Overweight on Stevanato Group, Lowers Price Target to $22
$22.00
(was $19.84)
Morgan Stanley
Wells Fargo Maintains Overweight on Stevanato Group, Lowers Price Target to $19
$19.00
(was $16.59)
Wells Fargo